Año 2023 / Volumen 115 / Número 12
Original
Effectiveness and safety of ustekinumab dose escalation in Crohn’s disease: a multicenter observational study

686-692

DOI: 10.17235/reed.2023.9402/2022

Raúl Vicente Olmedo Martín, Juan María Vázquez Morón, María del Mar Martín Rodríguez, Marta Lázaro Sáez, Álvaro Hernández Martínez, Federico Argüelles-Arias,

Resumen
Background: ustekinumab has proven effective in Crohn’s disease (CD). However, some patients will partially respond or lose response over time. Data supporting the effectiveness of dose escalation in this scenario is scarce. Aim: to evaluate the effectiveness of ustekinumab dose escalation in CD. Methods: patients with active CD (Harvey-Bradshaw ≥ 5) who had received intravenous (IV) induction and at least a subcutaneous (SC) dose were included in this retrospective observational study. Ustekinumab dose was escalated, either via shortening of the interval to six or four weeks or IV reinduction plus shortening to every four weeks. Results: ninety-one patients were included, and ustekinumab dose was escalated after a median of 35 weeks of treatment. At week 16 after intensification, steroid-free clinical response and remission were observed in 62.6 % and 25.3 % of patients, respectively. Systemic corticosteroids were discontinued in 46.7 % of patients who were on corticosteroids at baseline. Follow-up data beyond week 16 were available for 78 % of patients; at the last visit, 66.2 % and 43.7 % were in steroid-free clinical response and remission, respectively. After a median follow-up of 64 weeks, 81 % of patients were still treated with ustekinumab. Adverse events were reported in 4.3 % of patients; these were all mild and did not lead to hospitalization or discontinuation of treatment. Five patients (5.5 %) underwent surgical resection, with no immediate postsurgical complications. Conclusion: ustekinumab dose escalation was effective in recapturing response in over half of the patients. These findings suggest that dose escalation should be considered in patients who experience loss or partial response to the standard maintenance.
Resumen coloquial
Crohn's disease is a chronic inflammatory disorder that affects the digestive tract and causes significant impairment in quality of life. The available treatment options are limited and do not work for all patients. In addition, they can lose effectiveness over time, sometimes having to increase the dose or shorten the time between administrations to keep the patient free of symptoms. Ustekinumab is a biologic drug that blocks inflammatory mediators that has demonstrated efficacy in moderate-to-severe Crohn´s disease patients in clinical trials. In these clinical trials, a conventional dose authorized by regulatory agencies was tested. For this reason, given the scarcity of available data, this study aimed to evaluate the intensification of the Ustekinumab dose in a group of patients who either had no response to the drug or lost it to follow-up. To do this, a series of 91 patients from several reference hospitals were included and the symptomatic and analytical response and the durability of the treatment after the dose optimization strategy was analyzed. Almost 2 out of 3 patients responded to dose escalation and that approximately 80% were maintained on treatment beyond a year of starting this strategy. Furthermore, there were no documented security issues. These results encourage further exploration of the best way to optimize treatment with Ustekinumab in patients with Crohn's disease.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Artículos relacionados

Imagen en Patología Digestiva

Intestinal and perianal tuberculosis: an uncommon clinical presentation and challenging diagnosis

DOI: 10.17235/reed.2022.8988/2022

Imagen en Patología Digestiva

Enfermedad de Crohn cutánea periostomal por contigüidad

DOI: 10.17235/reed.2022.8909/2022

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Carta al Editor

Adnexal localization of Crohn’s disease and recurrent massive ovary cysts

DOI: 10.17235/reed.2016.4301/2016

Caso Clínico

Enfermedad de Crohn metastásica en pediatría

DOI: 10.17235/reed.2016.3948/2015

Carta al Editor

Debut conjunto de enfermedad de Crohn y síndrome de Sweet

DOI: 10.17235/reed.2015.3842/2015

Caso Clínico

Afectación ovárica en la enfermedad de Crohn: una complicación rara

DOI: 10.17235/reed.2015.3764/2015

Instrucciones para citar
Olmedo Martín R, Vázquez Morón J, Martín Rodríguez M, Lázaro Sáez M, Hernández Martínez Á, Argüelles-Arias F, et all. Effectiveness and safety of ustekinumab dose escalation in Crohn’s disease: a multicenter observational study. 9402/2022


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1016 veces.
Este artículo ha sido descargado 200 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 04/12/2022

Aceptado: 31/05/2023

Prepublicado: 14/06/2023

Publicado: 12/12/2023

Tiempo de revisión del artículo: 168 días

Tiempo de prepublicación: 192 días

Tiempo de edición del artículo: 373 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas